Wird geladen...
Mitogen activated protein kinase inhibitors: where are we now and where are we going?
Orally bioavailable compounds that target key intracellular signalling molecules are receiving increasing attention for the treatment of rheumatic diseases. The mitogen activated protein (MAP) kinases are especially attractive because they regulate both cytokine production and cytokine action. The M...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BMJ Group
2006
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1798373/ https://ncbi.nlm.nih.gov/pubmed/17038480 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2006.058388 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|